CoChat

Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma

Open access
Dhodapkar, Kavita M., Cohen, Adam D., Kaushal, Akhilesh, Garfall, Alfred L., Manalo, Renee Julia, Carr, Allison R., McCachren, Samuel S., Stadtmauer, Edward A., Lacey, Simon F., Melenhorst, J. Joseph, June, Carl H., Milone, Michael C., Dhodapkar, Madhav V. · 2022 · Blood Cancer Discovery
Cited by 115

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Chimeric antigen-receptor (CAR) T cells lead to high response rates in myeloma, but most patients experience recurrent disease. We combined several high-dimensional approaches to study tumor/immune cells in the tumor microenvironment (TME) of myeloma patients pre– and post–B-cell maturation antigen (BCMA)-specific CAR T therapy. Lower diversity of pretherapy T-cell receptor (TCR) repertoire, presence of hyperexpanded clones with exhaustion phenotype, and BAFF+PD-L1+ myeloid cells in the marrow correlated with shorter progression-free survival (PFS) following CAR T therapy. In contrast, longer PFS was associated with an increased proportion of CLEC9A+ dendritic cells (DC), CD27+TCF1+ T cells with diverse T-cell receptors, and emergence of T cells expressing marrow-residence genes. Residual tumor cells at initial response express stemlike genes, and tumor recurrence was associated with the emergence of new dominant clones. These data illustrate a dynamic interplay between endogenous T, CAR T, myeloid/DC, and tumor compartments that affects the durability of response following CAR T therapy in myeloma. Significance: There is an unmet need to identify determinants of durable responses following BCMA CAR T therapy of myeloma. High-dimensional analysis of the TME was performed to identify features of immune and tumor cells that correlate with survival and suggest several strategies to improve outcomes following CAR T therapy. See related commentary by Graham and Maus, p. 478. This article is highlighted in the In This Issue feature, p. 476

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2643-3230.bcd-22-0018

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 115

Metadata

Authors
Dhodapkar, K. M., Cohen, A. D., Kaushal, A., Garfall, A. L., Manalo, R. J., Carr, A. R., McCachren, S. S., Stadtmauer, E. A., Lacey, S. F., Melenhorst, J. J., June, C. H., Milone, M. C., & Dhodapkar, M. V.
Venue
Blood Cancer Discovery
Published
2022-08-26
Volume
3
Issue
6
Pages
490-501
ISSN
  • 2643-3230 (ISSN-L)
  • 2643-3249
OpenAlex
W4293149707
Cited by
115
References
12
FWCI
9.24
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma. https://app.cochat.ai/papers/10.1158/2643-3230.bcd-22-0018
The paper
Dhodapkar, K. M., Cohen, A. D., Kaushal, A., Garfall, A. L., Manalo, R. J., Carr, A. R., McCachren, S. S., Stadtmauer, E. A., Lacey, S. F., Melenhorst, J. J., June, C. H., Milone, M. C., & Dhodapkar, M. V. (2022). Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma. Blood Cancer Discovery. https://doi.org/10.1158/2643-3230.bcd-22-0018

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.